Cantor Fitzgerald Forecasts JSPR FY2025 Earnings

Jasper Therapeutics, Inc. (NASDAQ:JSPR) – Cantor Fitzgerald issued their FY2025 EPS estimates for shares of Jasper Therapeutics in a report issued on Tuesday, January 21st. Cantor Fitzgerald analyst P. Stavropoulos expects that the company will post earnings of ($4.24) per share for the year. The consensus estimate for Jasper Therapeutics’ current full-year earnings is ($4.47) per share.

Jasper Therapeutics (NASDAQ:JSPR) last posted its earnings results on Thursday, November 7th. The company reported ($1.24) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.09) by ($0.15).

JSPR has been the subject of a number of other reports. HC Wainwright reduced their price objective on shares of Jasper Therapeutics from $60.00 to $40.00 and set a “buy” rating for the company in a research note on Friday, January 10th. JMP Securities restated a “market outperform” rating and set a $70.00 price objective on shares of Jasper Therapeutics in a research report on Monday, January 6th. BMO Capital Markets began coverage on shares of Jasper Therapeutics in a research report on Friday, December 6th. They set an “outperform” rating and a $63.00 price objective on the stock. Finally, Royal Bank of Canada lowered their price objective on shares of Jasper Therapeutics from $68.00 to $48.00 and set an “outperform” rating on the stock in a research report on Thursday, January 9th. Ten equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Jasper Therapeutics has an average rating of “Buy” and a consensus price target of $67.75.

Jasper Therapeutics Price Performance

NASDAQ:JSPR opened at $6.01 on Wednesday. The firm has a market capitalization of $90.15 million, a P/E ratio of -1.27 and a beta of 2.18. Jasper Therapeutics has a one year low of $5.25 and a one year high of $31.01. The company’s 50-day simple moving average is $18.28 and its 200 day simple moving average is $19.24.

Institutional Trading of Jasper Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the company. Jane Street Group LLC purchased a new position in Jasper Therapeutics during the third quarter valued at $251,000. Samsara BioCapital LLC grew its stake in Jasper Therapeutics by 11.4% during the third quarter. Samsara BioCapital LLC now owns 584,642 shares of the company’s stock valued at $10,997,000 after acquiring an additional 59,642 shares in the last quarter. Wellington Management Group LLP purchased a new position in Jasper Therapeutics during the third quarter valued at $447,000. Ally Bridge Group NY LLC grew its stake in Jasper Therapeutics by 82.7% during the third quarter. Ally Bridge Group NY LLC now owns 399,466 shares of the company’s stock valued at $7,514,000 after acquiring an additional 180,852 shares in the last quarter. Finally, FMR LLC purchased a new position in Jasper Therapeutics during the third quarter valued at $722,000. 79.85% of the stock is currently owned by institutional investors.

About Jasper Therapeutics

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.